Score Overview
Explore the 2021 public Archive ranking →
Where Ionis Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- IONS
1996: 82.6% · 2021: 95.7% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 45.89 | — |
1 Year2025-09-29 | $ 64.15 | -28.46% |
5 Years2021-09-29 | $ 33.58 | 36.66% |
10 Years2016-09-29 | $ 35.57 | 29.01% |
20 Years2006-09-29 | $ 7.18 | 6x |
30 Years1996-09-27 | $ 14.41 | 218.51% |
All Time1991-05-17 | $ 9.22 | 397.68% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 | All Time1991-05-17 |
|---|---|---|---|---|---|---|---|
| Price | $ 45.89 | $ 64.15 | $ 33.58 | $ 35.57 | $ 7.18 | $ 14.41 | $ 9.22 |
| Return | — | -28.46% | 36.66% | 29.01% | 6x | 218.51% | 397.68% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 873M | -$ 564M | $ 2.05B |
| 2025 | $ 944M | -$ 381M | $ 2.67B |
| 2024 | $ 705M | -$ 453M | $ 2.29B |
| 2023 | $ 787M | -$ 366M | $ 2.33B |
| 2022 | $ 587M | -$ 269M | $ 1.99B |
| 2021 | $ 810M | -$ 28M | $ 2.11B |
| 2020 | $ 729M | -$ 487M | $ 1.89B |
| 2019 | $ 1.12B | $ 294M | $ 2.50B |
| 2018 | $ 599M | $ 273M | $ 2.08B |
| 2017 | $ 514M | $ 1.02B | |
| 2016 | $ 346M | -$ 86M | $ 667M |
| 2015 | $ 283M | -$ 88M | $ 803M |
| 2014 | $ 214M | -$ 38M | $ 810M |
| 2013 | $ 147M | -$ 60M | $ 708M |
| 2012 | $ 102M | -$ 65M | $ 408M |
| 2011 | $ 99M | -$ 84M | $ 343M |
| 2010 | $ 108M | -$ 61M | $ 472M |
| 2009 | $ 121M | $ 155M | $ 574M |
| 2008 | $ 107M | -$ 18M | $ 490M |
| 2007 | $ 58M | -$ 10M | $ 193M |
| 2006 | $ 14M | -$ 45M | $ 193M |
| 2005 | $ 40M | -$ 72M | $ 94M |
| 2004 | $ 42M | -$ 142M | $ 103M |
| 2003 | $ 49M | -$ 94M | $ 215M |
| 2002 | $ 80M | -$ 72M | $ 289M |
| 2001 | $ 53M | -$ 73M | $ 312M |
| 2000 | $ 37M | -$ 53M | $ 127M |
| 1999 | $ 33M | -$ 59M | $ 52M |
| 1998 | $ 39M | -$ 43M | $ 27M |
| 1997 | $ 32M | -$ 31M | $ 38M |
| 1996 | $ 22M | -$ 26M | $ 37M |
| 1995 | $ 13M | -$ 23M | $ 46M |
| 1994 | $ 10M | -$ 18M | $ 12M |
| 1993 | $ 12M | -$ 19M | $ 33M |
| 1992 | $ 8M | -$ 19M | $ 16M |
| IPO1991 | $ 6M | -$ 8M | $ 21M |
Ionis Pharmaceuticals Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 40M to $ 944M and net income went from -$ 72M to -$ 381M. Revenue increased in 14 of those 20 years; net income in 10.
Across Ionis Pharmaceuticals Inc's full reported history, from 1991 to 2025, revenue grew from $ 6M to $ 944M and net income went from -$ 8M to -$ 381M. Revenue increased in 66% of the years measured; net income in 45%.
Ionis Pharmaceuticals Inc currently holds a 20-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.
Membership
Continue IONS’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
